TYMS 2R3R polymorphism and DPYD [IVS]14+1G>A mutation genes in Mexican colorectal cancer patients

Martha Patricia Gallegos-Arreola; Guillermo Moises Zúñiga-González; Josefina Yoaly Sánchez-López; Alondra Yeraldi Naranjo-Cruz; Valeria Peralta-Leal; Luis E Figuera; Ana María Puebla-Pérez; Carlos Alberto Ronquillo-Carreón; Ana Graciela Puebla-Mora

doi:10.18388/abp.2017_2338

Martha Patricia Gallegos-Arreola Laboratorio de Genética Molecular División de Genética Centro de Investigación Biomédica de Occidente (CIBO), Instituto mexicano del seguro Social (IMSS) http://orcid.org/0000-0003-4539-1693
Guillermo Moises Zúñiga-González Mutagenesis Laboratory, Molecular Medicine Division, Western Biomedical Research Center, Western National Medical Center, Mexican Institute of Social Security, Guadalajara, Jalisco, Mexico
Josefina Yoaly Sánchez-López Genetics Division, Western Biomedical Research Center, Western National Medical Center, Mexican Institute of Social Security, Guadalajara, Jalisco, Mexico.
Alondra Yeraldi Naranjo-Cruz Genetics Division, Western Biomedical Research Center, Western National Medical Center, Mexican Institute of Social Security, Guadalajara, Jalisco, Mexico
Valeria Peralta-Leal Facultad de Medicina e Ingeniería en Sistemas Computacionales (FMeISC), Universidad Autónoma de Tamaulipas, Matamoros, Tamaulipas, México
Luis E Figuera Genetics Division, Western Biomedical Research Center, Western National Medical Center, Mexican Institute of Social Security, Guadalajara, Jalisco, Mexico
Ana María Puebla-Pérez Inmmunopharmacology Laboratory, Exact and Engineering Sciences University Center, University of Guadalajara, Guadalajara, Jalisco, Mexico
Carlos Alberto Ronquillo-Carreón UMAE, Specialty Hospital, Oncology, Western National Medical Center, Mexican Institute of Social Security, Guadalajara, Jalisco, Mexico
Ana Graciela Puebla-Mora UMAE, Specialty Hospital, Pathology6 Service, Western National Medical Center, Mexican Institute of Social Security, Guadalajara, Jalisco, Mexico

DOI: https://doi.org/10.18388/abp.2017_2338

Keywords: TYMS 2R/3R, colorectal cancer, DPYD [IVS]14 1G>A

Abstract

Objetive: To examine the association between TYMS 2R3R polymorphism and DPYD [IVS]14+1G>A mutation by comparing healthy subjects with colorectal cancer (CRC) patients from a Mexican population. Method: The genotyping of the 2R/3R was performed by polymerase chain reaction (PCR) and -[IVS]14+1G>A mutation by real-time PCR analysis. Results: The observed frequencies of the TYMS 2R3R polymorphism and the -[IVS]14+1G>A mutation on DPYD did not indicate an increased risk for CRC (p>0.05). An association between genotype and disease was evident. The distributions of the 2R/2R genotype and hematological toxicity (adjusted OR 2.26, 95% CI 1.54-4.45, p=0.0259), heterozygous (2R/3R) with tumor stage III-IV (OR 2.4, 95% CI 1.1-4.4, p=0.035) and 2R/2R-2R/3R in non-chemotherapy response CRC patients with hematological (OR 3.11, 95% CI 1.18-8.2, p=0.035) and gastric toxicities (OR 2.3, 95% CI 1.21-4.4, p=0.014) confirmed that this factor may contribute significantly to CRC susceptibility. Conclusion: TYMS 2R3R polymorphism and the -[IVS]14+1G>A mutation on DPYD was not associated with susceptibility for CRC. However, the genotypes 2R/2R and 2R/3R of TYMS polymorphism could contribute significantly to hematological and gastric toxicity in CRC patients in this sample population.

Author Biography

Martha Patricia Gallegos-Arreola, Laboratorio de Genética Molecular División de Genética Centro de Investigación Biomédica de Occidente (CIBO), Instituto mexicano del seguro Social (IMSS)

Diviisón de Genética, CIBO, IMSS